Purpose : To evaluate the correlation between the presence of a newly described mitochondrial DNA (mtDNA) mutation ( mtDNA 5286 ), patients' age, and in vitro fertilization (IVF) outcomes.
INTRODUCTION
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of mitochondrial DNA (mtDNA) mutations in the oocyte (1, 2) . The mitochondrial genome is a circular, 16,569 bp, histone-free DNA molecule that is present in one or more copies in every mitochondrion (3, 4) . Most mitochondrial proteins are encoded by the nuclear genome and are transported to the mitochondria by a complex shuttling system (5) . The mitochondrial genome encodes 13 proteins, 2 rRNAs, and 22 tRNAs. All mtDNA-encoded proteins are subunits of the mitochondrial energy-generating pathway, the oxidative phosphorylation system (6) .
Several human diseases occur as a direct result of mtDNA mutations, among them Leber hereditary optic neuropathy (LHON) and Kearns-Sayre Syndrome (KSS) (7, 8) . In addition, and consistent with the overall aging process, there is an increase in the rate of accumulation of somatic mtDNA mutations concomitant with a decrease in mitochondrial respiratory function (4, 9) . Accumulation of mtDNA mutations in a specific tissue is inversely correlated to its replicative 1058-0468/02/0200-0060/0 C 2002 Plenum Publishing Corporation potential and directly related to its metabolic state. Indeed, mtDNA mutations are more common in the brain and in striated muscle (7, 8, 10) .
More than 150 different types of mtDNA mutations have been identified, among which one of the most frequently observed is a 4977 bp deletion which occurs at a presumed "hot spot" and is called the common deletion or mtDNA 4977 . This mutation accumulates with age in various human tissues and has been proposed as a marker of natural aging (11) (12) (13) . While Keefe et al. (1) suggested that mtDNA 4977 is positively correlated with patients' age and may, therefore, serve as a marker of oocyte senescence, other studies have failed to confirm this observation (14) (15) (16) . Barritt et al. (16) detected 23 different mtDNA rearrangements in 50% of human oocytes and found no age-related change in the presence of mtDNA rearrangements in human oocytes. They did, however, note that the donor age of oocytes with mtDNA rearrangements was significantly lower than the donor age of oocytes without mtDNA rearrangements.
Employing the same set of nested-primers that is used to detect mtDNA 4977 , we now detected a previously undescribed 5286 bp mtDNA deletion ( mtDNA 5286 ) in human oocytes. In the current study, we evaluated the correlation between the presence of this newly described deletion with patients' age and IVF outcome.
MATERIALS AND METHODS

Subjects
All experiments were approved by the local Internal Review Board and met the guidelines for oocyte experimentation as outlined by the American Society of Reproduction Medicine (17) . Unfertilized human oocytes were obtained from patients undergoing IVF at the Sara Racine IVF Unit. The population treated by the unit is characterized by 30% having had more than four previous failed IVF cycles, and 27% of the patients are ≥40 years of age. Ovulation induction was achieved by a standard proto- Embryo morphology was scored from I to IV according to the shape of the blastomeres and the amount of detached anuclear fragments, as described previously (18) . Clinical pregnancies were defined by a sonographic demonstration of a gestational sac.
Sample Preparation
Unfertilized metaphase II (MII) oocytes which showed no evidence of fertilization (i.e., failure to demonstrate a second polar body and two pronuclei) were washed and collected in phosphate-buffered saline (PBS), frozen in liquid nitrogen, boiled for 10 min to completely lyse the cells, and stored at −20
• C until use. A total of 224 oocytes, retrieved from 81 patients, were analyzed. Only one or two unfertilized oocytes were available for analysis in 68% of the patients, whereas at least three oocytes were analyzed in 32%.
Polymerase Chain Reaction (PCR)
Standard PCR Strategy. The presence of mtDNA in single human oocytes was confirmed by standard PCR with the use of primers P4 and P5 for amplifying a fragment outside the deletion area (Table I ). The initial denaturation step was performed at 94
• C for 3 min. This was followed by 30 cycles of denaturation at 94
• C for 1 min, annealing at 60
• C for 1 min, elongation at 72
• C for 1 min, and final extension at 72
• C for 10 min. Amplification was performed in a final volume of 25 µL containing 50 pmol of each primer, 200 µM of each dNTP, and 2.5 U Taq polymerase. The resulting amplified fragment was 237 bp long (Table I) .
Nested-Primer PCR Strategy. A nested-primer PCR technique was used to detect the presence of mtDNA 4977 and mtDNA 5286 in human oocytes (Fig. 1) . The first step, outer PCR reaction, employed primers V1 and H35 (Table I) . PCR conditions were as follows: initial denaturation step at 94
• C for 3 min, followed by 30 cycles of denaturation at 94
• C for 10 min. The amplification was performed in a final volume of 25 µL containing 50 pmol of each primer (Gibco-BRL), 200 µM of each dNTP, and 2.5 U Taq polymerase (TaKaRa cat # TKR001A), using an MJ Thermocycler. For the nested PCR, amplification was performed for 30 cycles using the same conditions as for the outer PCR with the inner primers V3 and V2 (Table I) .
Precautions were taken to prevent contamination, and all experiments included buffer-only negative controls. Nested PCR products were separated on 10% polyacrylamide gel stained with ethidium bromide.
The mtDNA 4977 approximates the primerannealing sites such that the expected final PCR product is 511 bp long and similarly, the mtDNA 5286 results in a PCR product that is 200 bp long. Under the above-mentioned conditions, these sets of primers will not amplify across the whole nondeleted 5.5 kb region. However, even if such an amplification does occur, the resulting fragment will easily be distinguished from that of the deleted mtDNA.
DNA Sequencing Analysis
For direct sequencing, PCR products were purified by a DNA purification kit (Wizard PCR Preps, Promega). Sequencing analysis was carried out by using the ABI PRISM dye terminator cycle sequencing ready reaction kit (PE Applied Biosystems). An ABI 310 DNA sequencer performed the automated sequencing (PE Applied Biosystems).
Statistical Analysis
Patients were divided into two groups: the mtDNA 5286 positive group included all patients in whom the mutation was detected in at least one unfertilized oocyte and the mtDNA 5286 negative group included patients without this mutation in any of their oocytes. Statistical analysis was performed using the nonparametric Kruskal-Wallis one-way ANOVA test for comparing age, number of retrieved oocytes, fertilization and embryo cleavage, embryo quality, and the number of embryos transferred. The χ 2 analysis was used to compare pregnancy and implantation rates. A P value of <0.05 was considered statistically significant. 
RESULTS
The nested-primer PCR protocol was initially designed to detect mtDNA 4977 , which appears as a 0.5 kb fragment on gel electrophoresis. However, during preliminary experiments on mtDNA in human oocytes, an additional 0.2 kb fragment was detected in some of the oocytes using the same set of primers (Fig. 2) . Sequencing analysis of this fragment demonstrated that it represented a heretofore undescribed 5286 bp deletion ( mtDNA 5286 ). Alignment of the breakpoint region indicated that this novel deletion resulted from a second homologous recombination event via two highly homologous regions flanking the direct repeats responsible for mtDNA 4977 (Fig. 1) . These regions were composed of two 6 bp direct repeats with a 100% homology (repeats I and II), interrupted by 8 bp with a 50% homology, located at nt 8393-8412 and nt 13678-13697 (Fig. 3) . The homologous recombination occurred at repeat II (nt 8407-8412 and nt 13692-13697).
Amplification of total mtDNA in single oocytes by using primers P4 and P5 outside the expected deletions demonstrated a greater than 97% efficiency. mtDNA 5286 was found in 36 (16%) of the total of 224 oocytes that were analyzed (Table II) .
mtDNA 5286 was detected in at least one oocyte in 23 patients (the mtDNA 5286 positive group) and not detected in any of the 188 oocytes analyzed in the remaining 58 patients ( mtDNA 5286 negative group). Patients from the mtDNA 5286 positive group were significantly younger than those from the mtDNA 5286 negative group (30.9 ± 0.9 years vs. 33.8 ± 0.7 years, respectively, P = 0.03). In addition, fertilization rate was significantly lower in the mtDNA 5286 positive group (28.9% ± 4.8% compared to 42.1% ± 3.0% in the mtDNA 5286 negative group; P = 0.01) (Table II) . No other outcome variable was significantly different between the two groups.
In comparison, mtDNA 4977 was found in 143 (64%) of the 224 oocytes analyzed. In 66 patients, this deletion was detected in at least one oocyte, while none were found in any of the oocytes in the remaining 15 patients. When comparing patients with or without mtDNA 4977 in their oocytes, no statistically significant difference was noted in the patients' age (32.9 ± 0.7 years versus 33.1 ± 1.5 years, respectively, P = 0.19) or any of the IVF outcome variables, including fertilization rate (37.2% ± 3.0% vs. 43.4% ± 5.5%, respectively, P = 0.26), embryo quality, and clinical pregnancy rates.
DISCUSSION
Women experience a decline in their reproductive potential with age. This trend culminates in a complete loss of fertility by midlife, despite the fact that oocytes may still be present within the ovary. This age-related decline in fertility has been attributed to oocyte senescence. However, it is yet unclear what biochemical or molecular processes underlie this phenomenon. mtDNA mutations accumulate with age, especially in nondividing tissues. It is therefore tempting to speculate that oocyte senescence is the result of an age-related accumulation of mtDNA mutations causing respiratory dysfunction and thereby disturbing proper occyte maturation (1). This is due to the fact that meiosis involves tightly choreographed movements of chromosomes and organelles, a high energy-requiring process in which mitochondria have been shown to play an important role (19) (20) (21) . To test this hypothesis, Keefe et al. analyzed the correlation between age and the presence of mtDNA 4977 in unfertilized oocytes from women undergoing IVF (1). They found a significantly higher rate of oocytes with mtDNA 4977 in women >38 years of age compared to younger ones. Subsequent studies, however, found no direct relationship between age and the presence of mtDNA 4977 in human oocytes and embryos (14, 15) . Our results concur with those of Chen et al. (14) , Brenner et al. (15) , and Barritt et al. (16) in that no correlation was found between the mtDNA 4977 in oocytes, patients' age, and IVF outcome. It may, therefore, be contended that mtDNA 4977 is not a marker of oocyte senescence. There is, however, a significantly higher proportion of oocytes harboring mtDNA 4977 compared to embryos (47 and 20%, respectively [15] ). Those authors suggested that with embryo development, a mitochondrial "bottleneck" filters out the mutated mtDNA, thus eliminating the sporadic mutations that accumulate in oocytes during oogenesis. Alternatively, it was speculated that oocytes harboring the mtDNA mutation are less likely to develop into embryos (15, 16, 22, 23) .
The newly described mtDNA 5286 was detected fortuitously with the same primer set that had been used to detect mtDNA 4977 . The mtDNA 5286 was found in only 16% of unfertilized oocytes, raising the question of why the mtDNA 5286 is less frequent than mtDNA 4977 . Although the regions of homology responsible for the mtDNA 5286 span 20 bp, they share only 80% homology, whereas the repeats responsible for mtDNA 4977 , albeit shorter in length (13 bp), share 100% homology throughout their length. For that reason, a homologous recombination resulting in mtDNA 5286 is less likely to occur. As for why the mtDNA 5286 had not been previously detected, the answer lies in the fact that previous studies used either a hemi-nested PCR approach or a long-range PCR, followed by a second round PCR for the detection of mtDNA 4977 (14, 15) . In contrast, we used a nested-primer PCR strategy which is more sensitive as manifested by the higher rate of mtDNA 4977 in our study (64%) compared to others (33-49%) (1, 14, 15) . Moreover, previous studies used agarose gel electrophoresis whereas we used acrylamide gel, which may have also improved the detection threshold.
There is an age-related accumulation of mtDNA mutations in human tissues, but there is insufficient evidence to suggest that this occurs in human oocytes. Herein, we demonstrate that women harboring the mtDNA 5286 in their oocytes were significantly younger than those in whom this mutation was not detected (30.9 ± 0.9 years and 33.8 ± 0.7 years, respectively, P < 0.05). The same phenomenon was also observed for other mtDNA rearrangements (16) .
What effect can the presence of infrequent mtDNA mutations have on oocyte respiratory function? Previous studies estimated that the frequency of mtDNA 4977 in oocytes in only 0.01-0.1%. Given that the estimated number of mitochondrial genomes in an oocyte is ∼100,000, it is thus estimated that each oocyte contains ∼10 to 100 mtDNA 4977 copies (14) . The frequency of mtDNA 5286 and other mutations may be even lower. Hence, the overall frequency of such mtDNA mutations is probably too low to result in any degree of respiratory dysfunction. Instead, we suggest that the presence of such infrequent mtDNA mutations may serve as a marker, and not the cause, of decreased oocyte function.
A decline in oocyte quality, as manifested by a decreased fertilization rate, is often referred to as the "egg factor," and is commonly associated with patients' age (24, 25) . Occassionally, however, younger women may also demonstrate a reduced fertilization rate that is attributed to the "egg factor." The fact that the mtDNA 5286 was more frequent in unfertilized oocytes from younger women led us to hypothesize that this mutation may be a marker for an "egg factor" that is not age-related. This hypothesis may be supported by the fact that patients who have the mtDNA 5286 in their unfertilized oocytes had a significantly lower fertilization rate than those who did not (28.9% vs. 42.1%). The caveat to this statement is that the analysis was performed on unfertilized oocytes, and it is not known whether the findings can be generalized to the embryos transferred into patients. We, as others, have not been able to examine the mutation in all MII oocytes because of ethical constraints. The common assumption is that unfertilized oocytes represent, at least in part, the status of the overall oocyte population. It should be stressed that 30% of the women treated by the unit had had more than four previous failed IVF cycles and that 27% of them were ≥40 years of age. Nevertheless, during the study period, the overall clinical pregnancy rate per cycle was 24% and the take home baby rate was 17%. However, insofar as only oocytes that failed to fertilize in IVF were analyzed for the presence of the mtDNA, this selected group of patients demonstrated lower than our usual fertilization rates and, as a consequence, lower pregnancy rates.
Another issue that requires further investigation is the precise quantification of mtDNA 5286 in single human oocytes. However, the nested PCR approach used in this study is qualitative rather than quantitative; thus, the threshold above which the mutation will have an impact upon oocyte metabolism awaits further investigation.
The findings of the present study suggest that the presence of the novel mtDNA 5286 may serve as a non-age-related marker for decreased oocyte quality in IVF. It could, therefore, predict fertilization failure and provide a potential indicator of failure rate in IVF.
